Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2020 | Personalizing immunotherapy beyond PDL1 expression

Marleen Kok • 14 May 2020
ESMO Breast 2020
Breast Cancer Antibodies Atezolizumab Durvalumab Nab-paclitaxel Nivolumab Pembrolizumab
I-SPY IMpassion130 KEYNOTE-012

Marleen Kok, MD, PhD, Netherlands Cancer Institute, Amsterdam, The Netherlands, discusses personalizing immunotherapy beyond PD-L1 expression. Specifically discussed is the IMpassion130 trial (NCT02425891), neoadjuvant data and tumor mutational burden. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Marleen Kok

1:08
St Gallen 2023: de-escalation, personalized treatment & adjuvant IO following neoadjuvant IO
Marleen Kok • 16 Mar 2023
0:58
Personalizing approaches in early-stage TNBC
Marleen Kok • 16 Mar 2023
3:17
Multiplexed analysis and spatial histology to predict response to immunotherapy in breast cancer
Marleen Kok • 16 Mar 2023
1:34
Strategies to improve the response to immunotherapy in TNBC
Marleen Kok • 16 Mar 2023

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals